An observational study in Platelet Reactivity, sponsored by Pierre Fontana. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2015-12-02.
Sponsored by Pierre Fontana · Observational
The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients.
The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients using a system biology approach that include proteomics analysis of selected platelet sub-fractions in patients displaying extreme phenotype.
Main objective:
Secondary objectives:
Pierre Fontana is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Symptomatic atherothrombotic patients treated with aspirin.
Exclusion Criteria:
proteome profile of platelet hyperreactivity
to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients
Time frame: cross sectional
platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin
Time frame: cross sectional
genetic polymorphisms associated with platelet hyperreactivity
Time frame: cross sectional
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pierre Fontana